ALNY Q2 2018 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+87.7% YoY

Gross Profit

$30M100.0% margin

Operating Income

-$192M-643.2% margin

Net Income

-$164M-546.9% margin

EPS (Diluted)

$-1.63

QoQ Revenue Growth

+36.6%

Cash Flow

Operating Cash Flow

-$103M

Free Cash Flow

-$125M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$169M

Stockholders' Equity

$1.6B

Cash & Equivalents

$361M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$16M	+87.7%
Gross Profit	$30M	$16M	+87.7%
Operating Income	-$192M	-$120M	-59.7%
Net Income	-$164M	-$118M	-38.1%